Our research has led us to discover that patients suffering from inflammatory bowel diseases
lack a crucial bacterium and, therefore, do not have a fair chance to fight their conditions.

We have developed a single bacterial strain drug candidate to deliver the key bacteria
Faecalibacterium praustnizii for the treatment of inflammatory bowel diseases,
starting with Crohn's Disease as a first indication.